Logo 1 Logo 2

Clinical Trial Details

Trial ID: L0657
Source ID: NCT00228449
Associated Drug: Peginesatide
Title: Peginesatide for Anemia in Chronic Hemodialysis Patients
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Anemia|Chronic Kidney Disease|Chronic Renal Failure
Interventions: DRUG: peginesatide
Outcome Measures: Primary: Average weekly hemoglobin and hemoglobin change from baseline, Baseline to Week 27 | Secondary: Percentage of participants with hemoglobin within 1.0 gram per deciliter (g/dL) above or below baseline, Baseline to Week 25|Percentage of participants who maintain hemoglobin within 9.5-13.0 g/dL, Baseline to Week 25|Percentage of participants who maintain hemoglobin within 11.0-13.0 g/dL, Baseline to Week 25
Sponsor/Collaborators: Sponsor: Affymax
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 165
Study Type: INTERVENTIONAL
Study Designs: Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2005-07
Completion Date: 2007-05
Results First Posted:
Last Update Posted: 2012-12-21
Locations: Research Facility, Birmingham, Alabama, 35213, United States|Research Facility, Pine Bluff, Arkansas, 71603, United States|Research Facility, Los Angeles, California, 90095, United States|Research Facility, Mountain View, California, 94041, United States|Research Facility, Lauderdale Lakes, Florida, 33313, United States|Research Facility, Pembroke Pines, Florida, 33028, United States|Research Facility, Shreveport, Louisiana, 71101, United States|Research Facility, Detroit, Michigan, 48202, United States|Research Facility, Minneapolis, Minnesota, 55404, United States|Research Facility, New York, New York, 10128, United States|Research Facility, Canton, Ohio, 44718, United States|Research Facility, Nashville, Tennessee, 37205, United States|Research Facility, San Antonio, Texas, 78215, United States|Research Facility, Norfolk, Virginia, 23507, United States
URL: https://clinicaltrials.gov/show/NCT00228449